(2026). PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model. Molecular Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"PAK1 Activation Drives Divergent Resistance Mechanisms to Aromatase Inhibition and Tamoxifen in a Luminal: A Breast Cancer Model."
Molecular Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"PAK1 Activation Drives Divergent Resistance Mechanisms to Aromatase Inhibition and Tamoxifen in a Luminal: A Breast Cancer Model."
Molecular Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.